$ZYNE Zynerba Trade setup

Very high short interest at 30%
Stock is currently well below the average analyst price target of $18 and a BUY rating.
Company profile
Zynerba Pharmaceuticals , Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Do you want to GAIN an Edge on Wall Street?

1) Sign Up for Free @

2) Follow our Telegram Channel @

3) Join our LIVE CHAT on our Discord @


ZYNE will be one of the stocks to be removed from the Russell 3000 on Friday 26th.

I would be very careful to place a trade this week.

Check out for the Russell reconstitution.
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out